E
ABOS icon

Ergoteles’s Acumen Pharmaceuticals ABOS Stock Holding History

Ergoteles’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,113
Closed -$52K – 1498
2022
Q2 		$52K Buy
+11,113
New +$41.8K ﹤0.01% 1557
2022
Q1 		– Sell
-77,152
Closed -$522K – 1165
2021
Q4 		$522K Buy
+77,152
New +$848K 0.02% 623

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PFO
Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return

Ergoteles's ABOS Position: Q3 2022 in Review

Ergoteles sold out of Acumen Pharmaceuticals (ABOS) in Q3 2022, closing a stake of 11,113 shares — an estimated $52K sold.

Ergoteles first reported a position in ABOS in Q4 2021 and held it in 2 quarters. The position peaked at $522K in Q4 2021. 50 funds tracked by Wall St. Rank hold ABOS as of Q3 2022.

  • Ergoteles reported no remaining Acumen Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Ergoteles sold 11,113 Acumen Pharmaceuticals shares in Q3 2022, an estimated $52K.
  • Ergoteles first reported a position in Acumen Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Ergoteles's Acumen Pharmaceuticals position peaked at $522K in Q4 2021.
  • 50 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.